Patents by Inventor Rhiannon THOMAS-TRAN

Rhiannon THOMAS-TRAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230102927
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: April 19, 2022
    Publication date: March 30, 2023
    Applicants: Gilead Sciences, Inc., Gilead Sciences, Inc.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
    Publication number: 20230024302
    Abstract: Compounds that inhibit PI3K?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3K?.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 26, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Jeremy Thomas Andre FOURNIER, Jenna Leigh JEFFREY, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Artur Karenovich MAILYAN, Guillaume MATA, Dillon Harding MILES, Jay Patrick POWERS, Ehesan UI SHARIF, Rhiannon THOMAS-TRAN, Xuelei YAN
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230021705
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: April 19, 2022
    Publication date: January 26, 2023
    Inventors: Megan K. Armstrong, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Chao-I Hung, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20220298148
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 22, 2022
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20220288030
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
    Type: Application
    Filed: January 27, 2021
    Publication date: September 15, 2022
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20220144808
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: October 22, 2021
    Publication date: May 12, 2022
    Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
  • CD73 INHIBITORS
    Publication number: 20210346353
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: August 26, 2019
    Publication date: November 11, 2021
    Inventors: Joel BEATTY, Laurent Pierre Paul DEBIEN, Samuel Lawrie DREW, Jeremy FOURNIER, Rebecca Louise GRANGE, Steven Donald JACOB, Jenna Leigh JEFFREY, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Jay Patrick POWERS, Anh Thu TRAN, Rhiannon THOMAS-TRAN, Xuelei YAN
  • Azolopyrimidine for the treatment of cancer-related disorders
    Patent number: 11072597
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: July 27, 2021
    Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
  • Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
    Patent number: 11045472
    Abstract: Compounds of Formula I that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: June 29, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif, Rhiannon Thomas-Tran
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20210171499
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: October 22, 2020
    Publication date: June 10, 2021
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20210101880
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: July 2, 2019
    Publication date: April 8, 2021
    Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
  • QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20200069689
    Abstract: Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: May 3, 2018
    Publication date: March 5, 2020
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF, Rhiannon THOMAS-TRAN
  • Azolopyrimidine for the treatment of cancer-related disorders
    Patent number: 10399962
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 3, 2019
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
  • AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20180215730
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: January 19, 2018
    Publication date: August 2, 2018
    Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN